165 cases of monoclonal antibody antineoplastic adverse drug reactions report analysis
10.13699/j.cnki.1001-6821.2015.13.023
- VernacularTitle:165例单抗类抗肿瘤药物不良反应报告分析
- Author:
Juan WANG
1
;
Qi CUI
;
Hui-Zhen WU
;
Su-Ying YAN
Author Information
1. 首都医科大学 宣武医院 药剂科
- Keywords:
monoclonal antibody;
anticancer drug;
adverse drug reaction
- From:
The Chinese Journal of Clinical Pharmacology
2015;(13):1296-1298
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analysis of the monoclonal antibody anticancer drugs the characteristics of adverse drug reactions ( ADR ) and related factors, and provide reference for clinical rational drug use . Methods A total of 165 ADR monoclonal antibody cases drugs collected from January 2006 to August 2012 in Beijing adverse drug reaction center to statistical and analyses.Results In the 165 ADR reports, males were more than females, elderly in 50 to 80 years people were the main population of ADR.The clinical manifestations of the ADR in systemic reactions were the most common , followed by blood system damage , skin and accessories. The recovery and improvement were accounted for 88.48%.Resistance in the analysis of the monoclonal antibody drug ADR report. The rituxan accounts for most general adverse drug reactions, the most serious adverse drug reaction ratio of cetuximab . Conclusion Monoclonal antibody anticancer drugs such as ADR and way to patients′gender, age, drug delivery, drug dosage form.
